XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration and License Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2016
target
Mar. 31, 2022
USD ($)
obligation
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License related revenue   $ 30,000,000 $ 1,626,000  
GSK Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Contract with customer, expiration period   10 years    
Number of performance obligations | obligation   3    
Transaction price   $ 90,264,000    
GSK Agreement | License        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License related revenue   30,000,000 1,626,000  
GSK Agreement | License | Transferred at Point in Time        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront payment   85,000,000    
License related revenue       $ 85,000
GSK Agreement | License | Transferred over Time        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional payments to be received   4,314,000    
GSK Agreement | Transition Services        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License related revenue   0 362,000  
GSK Agreement | Transition Services | Transferred over Time        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional payments to be received   950,000    
GSK Agreement | Supply Services        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
License related revenue   0 1,264,000  
GSK Agreement | Clinical Milestone Payment        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Potential milestones payment   90,000    
GSK Agreement | Regulatory Milestone Payment        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Potential milestones payment   155,000    
GSK Agreement | Sales Milestone Payment        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Potential milestones payment   485,000    
Novartis Collaboration        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of option targets | target 4      
Number of option targets purchased | target 3      
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc.        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue   0 $ 0  
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc. | Development Milestone        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Potential milestones payment   325,000,000    
Novartis Collaboration | Novartis Institutes for Biomedical Research, Inc. | Sales Milestone        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Potential milestones payment   $ 200,000,000